MTOR and cancer: Both the PKM2 inhibitor Compound 3K and the SIRT inhibitor MHY2245 can effectively suppress PKM2 expression and disrupt glycolysis metabolism by modulating the Akt/AMPK/mTOR pathway, thereby inducing G2/M cell cycle arrest, autophagic cell death, and inhibiting cancer cell proliferation as well as colony formation ability 101, 102.